An urgent need exists for new antifungal compounds to treat fungal infections in immunocompromised patients. The aim of the current study was to investigate the potency of a novel antifungal compound, MYC-053, against the emerging yeast and yeast-like pathogensCandida glabrata,Candida auris,Cryptococcus neoformans, andPneumocystisspecies.